Peter Dobranowski

We are excited to announce the publication of our new study. This work explores the relationship between dietary inflammatory potential and the development and progression of IBD. ➡️sciencedirect.com/science/ar…

As we wind down 2023, I offer here a 🧵of my top #IBD papers published this year. These are exceptional. And the good news is this is not a short list. I have categorized them into areas I think are important and deserve the most focus of our collective efforts. But first, some "thank you"s and a personal look back at 2023. Mostly, I want to profoundly thank the GI clinicians and researchers who connected with me this year, on @X , on WhatsApp, via Zoom, at #DDW, at ICN's Fall Community Conference, and at AHN's IBD Summit. You are the best of the best and I value you all more than I can say. This year, I once again had the great pleasure to interview some of you about your research (see @propelacure's YouTube channel). These were highlights for me and your work is in the 🧵below. Some of you were incredibly kind to ask for my input or assistance with your papers. I enjoyed this thoroughly and value your thinking and your approaches. This process of academic publishing has been truly insightful, frustratingly long, and I now have first-hand experience with reviewer #2. More than anything, it re-affirmed for me this year that we have many brilliant IBD researchers but that academic publishing in journals, as it works today, is not the most efficient or best way to get ideas and data--particularly paradigm-challenging ideas or data--out to the community. It certainly does not serve patients and their families with a sense of urgency to advance knowledge, therapies and cures. I may write more about this at some point. I also had the immense privilege to kickoff and host, with amazing collaboration and support from Propel and @connecttocure--two wonderful nonprofits deeply devoted to IBD patients--the Roadmap to a Cure, bringing together 15 and then 25 of the most brilliant IBD researchers from all over the world with a variety of areas of expertise, perspectives, and career stages to brainstorm about IBD pathogenesis, prevention, and cures of IBDs. My greatest challenge now looking to 2024 is to leverage this amazing group's goodwill and expertise to drive progress for patients within a framework that you are all used to working in, which frankly differs from how we operate in the business world. But I am optimistic and will have more to share soon. I am sorry I have been more quiet, but BIG things require iteration, deep thinking, and behind the scenes work, which has been my focus these last few months. I especially want to thank @guthealthmd and @bverstockt for your invaluable guidance, leadership, and belief in what is possible. I am also deeply grateful to @ImproveCareNow. This organization will continue to be my nonprofit focus. Thank you for continuing to strive to make meaningful quality improvements that improve the lives of children with IBD, and that of their families. I am grateful to @ssaeed94, Kristin, @PeterAMargolis and Missy for their leadership, for allowing me to (at times) challenge the status quo, for giving a real voice to parents/caregivers, and for supporting the incredible community of parents I have the privilege to work with, especially my national co-chair, Heidi, our dedicated leadership team, and former chair extraordinaire, @jmmh123. A shoutout to two of the physicians who partner with us at @ICNParents and always say YES, @SCKimIBDMD and @JeremyAdlerMD. And to @Flat_Jennie for partnering with us on an exciting project in progress, for being a phenomenal leader, and for generally doing so much for so many. Definitely a shining🌟in the world of IBD. 2024 is going to be exciting. It will be when personal and professional missions align: 20+ years in pharma, 7 years of experience with #IBD, the connections, insights, and efforts of these last years, and collective passion and drive will take shape in a new biotech company that is mission-driven to develop novel non-immunosuppressive therapeutics to improve the lives of #UC, #Crohn's and #Celiac patients and their families. Together with an outstanding business partner I connected with right here on @X, and who really provided the vision and the push, we are working hard to do what is not currently being done in the pharma pipeline--advancing truly novel, best-in-class, and promising therapeutics. And so, with all of that, please enjoy this thread of my top papers of 2023. Thank you to EVERYONE who worked on these.